​

Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Nektar Therapeutics Ownership Summary

Nektar Therapeutics is owned by 13.87% institutional investors, 0.66% insiders, and 85.47% retail investors. Bvf inc/il is the largest institutional shareholder, holding 9.06% of NKTR shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.57% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNektar Therapeutics13.87%0.66%85.47%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bvf inc/il1.28M9.06%$72.64M
Blackrock15.16M7.78%$18.79M
Vanguard group948.65K6.73%$53.98M
Morgan stanley929.15K6.60%$52.87M
Farallon capital management791.00K5.62%$45.01M
Blackrock funding, inc. /de609.11K4.32%$34.66M
Two sigma investments, lp434.24K3.08%$24.71M
Nantahala capital management418.52K2.97%$23.81M
22nw, lp331.12K2.35%$18.84M
Emerald advisers323.25K2.29%$18.39M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
22nw, lp331.12K8.88%$18.84M
Great point partners300.00K7.04%$17.07M
Stonepine capital management85.00K3.93%$4.84M
Deuterium capital management37.35K3.08%$2.13M
Bvf inc/il1.28M2.94%$72.64M
Superstring capital management lp51.27K2.87%$2.92M
Propel bio management49.00K2.79%$2.79M
Boxer capital management125.00K2.27%$7.11M
Allostery investments lp4.00K1.32%$103.36K
Diadema partners lp75.00K1.09%$4.27M

Top Buyers

HolderShares% AssetsChange
Blackrock15.16M0.00%9.28M
Altium capital management lp3.00M0.79%2.99M
Bvf inc/il1.28M2.94%1.28M
Morgan stanley929.15K0.00%857.01K
Farallon capital management791.00K0.18%791.00K

Top Sellers

HolderShares% AssetsChange
Samlyn capital---9.67M
Eventide asset management---6.65M
Almitas capital---4.61M
Jacobs levy equity management---3.01M
Millennium management2.29M0.00%-2.24M

New Positions

HolderShares% AssetsChangeValue
Bvf inc/il1.28M2.94%1.28M$72.64M
Farallon capital management791.00K0.18%791.00K$45.01M
Emerald advisers323.25K0.59%323.25K$18.39M
Jefferies financial group303.20K0.08%303.20K$17.25B
Great point partners300.00K7.04%300.00K$17.07M

Sold Out

HolderChange
Cornerstone planning group-5.00
Clearstead advisors-5.00
United community bank-7.00
Assetmark-22.00
Capital performance advisors llp-66.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202537-66.36%1,954,060-74.48%130.47%24-17.24%6-91.67%
Jun 30, 202537-77.30%2,048,084-98.35%140.42%10-86.49%27-44.90%
Mar 31, 20258-94.59%15,114,671-88.63%70.18%2-97.14%4-88.89%
Dec 31, 2024137-2.84%129,034,595-8.31%611.36%646.67%33-8.33%
Sep 30, 20241413.68%140,729,0353.96%671.39%61-15.28%365.88%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Eventide Healthcare & Life Sciences I6.65M3.57%-
Vanguard US Total Market Shares ETF5.72M3.08%-
Vanguard Total Stock Mkt Idx Inv524.03K2.93%142.38K
iShares Russell 2000 ETF4.62M2.48%-
PRIMECAP Odyssey Aggressive Growth188.82K1.09%-42.10K
iShares Russell 2000 Value ETF1.66M0.89%-
Fidelity Small Cap Index1.83M0.70%-
Vanguard Institutional Extnd Mkt Idx Tr120.87K0.68%-52.78K
Vanguard Strategic Equity Inv101.14K0.58%10.00
Emerald Growth A90.20K0.50%90.20K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 25, 2025Zalevsky Jonathan Chief R&D OfficerSell$62.80K
Nov 25, 2025Wilson Mark Andrew Chief Legal OfficerSell$34.20K
Nov 25, 2025ROBIN HOWARD W President & CEOSell$119.80K
Sep 09, 2025ROBIN HOWARD W President & CEOSell$58.30K
Sep 09, 2025ROBIN HOWARD W President & CEOSell$55.69K

Insider Transactions Trends

DateBuySell
2025 Q4-3
2025 Q3-20
2025 Q2-3
2025 Q1-3
2024 Q4-8

NKTR Ownership FAQ

Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 13.87%, followed by 0.66% insiders and 85.47% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 45.22%, which Nektar Therapeutics falls below.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Bvf inc/il (1.28M shares, 9.06%), Blackrock (15.16M shares, 7.78%), and Vanguard group (948.65K shares, 6.73%). Together, they hold 23.58% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

22nw, lp is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.88% of its assets in 331.12K Nektar Therapeutics shares, valued at 18.84M$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Nektar Therapeutics shares, with 3.57% of its total shares outstanding invested in 6.65M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools